Home > Boards > US Listed > Biotechs > BrainStorm Cell Therapeutics Inc. (BCLI)

BrainStorm's NurOwn shows encouraging action in lung inflammation model

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 112
Posts 24,615
Boards Moderated 7
Alias Born 02/07/04
160x600 placeholder
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/1/2020 4:53:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/25/2020 4:16:53 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/25/2020 4:15:36 PM
Brainstorm Announces Grant of a New Japanese Patent for NurOwn® PR Newswire (US) - 9/16/2020 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/10/2020 4:08:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/3/2020 4:06:53 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/10/2020 6:07:14 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/5/2020 7:01:27 AM
BrainStorm Announces Financial Results for the Second Quarter of 2020 and Provides a Corporate Update PR Newswire (US) - 8/5/2020 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 5:11:22 PM
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update PR Newswire (US) - 7/27/2020 7:58:00 AM
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS GlobeNewswire Inc. - 7/23/2020 7:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:16:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:10:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:05:43 PM
BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer's Disease Program PR Newswire (US) - 7/8/2020 5:31:00 AM
BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS PR Newswire (US) - 7/2/2020 6:49:00 AM
BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar PR Newswire (US) - 7/1/2020 8:50:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/26/2020 5:02:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/26/2020 5:01:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/26/2020 5:01:04 PM
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for the Treatment of Alzheimer's Disease PR Newswire (US) - 6/24/2020 7:00:00 AM
BrainStorm Granted SME Status by the European Medicines Agency GlobeNewswire Inc. - 6/15/2020 9:00:10 AM
BrainStorm to Present at the Raymond James Human Health Innovations Conference PR Newswire (US) - 6/11/2020 7:28:00 AM
The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study PR Newswire (US) - 6/9/2020 6:00:00 AM
midastouch017   Friday, 07/24/20 08:13:54 AM
Re: midastouch017 post# 2744
Post # of 2819 
BrainStorm's NurOwn shows encouraging action in lung inflammation model

Jul. 23, 2020 8:00 AM ET|About: Brainstorm Cell Therap... (BCLI)|By: Douglas W. House, SA News Editor

BrainStorm Cell Therapeutics (NASDAQ:BCLI) announces encouraging results from a preclinical study assessing NurOwn (MSC-NTF cells) in a mouse model of lipopolysaccharide (LPS)-induced acute respiratory syndrome (ARDS).

Intratracheal administration of NurOwn-derived exosomes showed statistically significant improvements in multiple lung parameters. MSC-NTF cell-derived exosomes also demonstrated a superior effect compared to exosomes derived from naïve mesenchymal stem cells (MSC) from the same donor.

The company regards the results as the first milestone in developing NurOwn for the treatment of severe COVID-19 infection.

It plans to submit the data for publication.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences